# A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal C

Source: https://onco.cc/trials/nct06979908/  
OnCo record `nct06979908` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of fruquintinib, sintilimab and tucidinostat (chidamide) in colorectal cancer, run by The First Hospital of Jilin University, now recruiting.

## Summary

A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer is a phase 2, interventional study registered as NCT06979908 by The First Hospital of Jilin University, with a registry enrolment figure of 46 participants, started 2025-01-22 and due to reach its primary completion in 2026-07-22. Interventions recorded: Fruquintinib+Sintilimab+Chidamide. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: PFS. Colorectal eligibility wording from the registry: "* Histologically confirmed colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06979908
- Phase: 2
- Setting: A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer
- Sponsor: The First Hospital of Jilin University
- Enrolled: 46

## Sources

- ClinicalTrials.gov NCT06979908: https://clinicaltrials.gov/study/NCT06979908

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Fruquintinib](https://onco.cc/drugs/fruquintinib/), [Sintilimab](https://onco.cc/drugs/sintilimab/), [Tucidinostat (chidamide)](https://onco.cc/drugs/tucidinostat/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06979908.json